Fas/APO-1 Gene Transfer for Human Malignant Glioma

Cancer Research

Volumn 55, Issue 13, 1995, Pages 2936-2944

  Weller, Michael ^a   Malipiero, Ursula ^a   Rensing Ehl, Anne ^a   Barr, Philip J ^b   Fontana, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LXR Biotechnology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; RECEPTOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; GENE TRANSFER; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES; ANTIGENS, CD95; ANTIGENS, SURFACE; APOPTOSIS; BASE SEQUENCE; CYCLOHEXIMIDE; DEXAMETHASONE; DNA PRIMERS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIOMA; HUMAN; IN VITRO; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0029073752     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Merchant, R. E., Ellison, M. D., and Young, H. F. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J. Neuro-Oncol., 8: 173–188, 1990.
2. Hayes, R. L. The cellular immunotherapy of primary brain tumors. Rev. Neurol., 148: 454–466, 1992.
3. Deen, F. D., Chiarado, A., Grimm, E. A., et al. Brain tumor working group report on the 9th International Conference on Brain Tumor Research and Therapy. J. Neuro-Oncol., 16: 243–272, 1993.
4. Jaeckle, K. A. Immunotherapy of malignant glioma. Semin. Oncol., 21: 249–259, 1994.
5. Fontana, A., Hengartner, H., De Tribolet, N., and Weber, E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J. Immunol., 132: 1837–1844, 1984.
6. Wrann, M., Bodmer, S., De Martin, R., Siepl, C., Hofer-Warbinek, R., Frei, K., Hofer, E., and Fontana, A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J., 6: 1633–1636, 1987.
7. De Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Wrann, M., Schliisener, H., Seifert, J. M., Bodmer, S., Fontana, A., and Hofer, E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J., 6: 3673–3677, 1987.
8. Bodmer, S., Strommer, K., Frei, K., Siepl, C., De Tribolet, N., Heid, L., and Fontana, A. Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J. Immunol., 143: 3222–3229,1989.
9. 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol., 24: 1293–1300, 1994.
10. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med., 777; 195–200, 1993.
11. Vignaux, F., and Golstein, P. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway? Eur. J. Immunol., 24: 923–927, 1994.
12. Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., and Golstein, P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (Washington DC), 265: 528–530, 1994.
13. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (Lond.), 370: 650–652, 1994.
14. Nagata, S., and Suda, T. Fas and Fas ligand: Ipr and gld mutations. Immunol. Today, 16: 39–43, 1995.
15. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S. I., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233–243, 1991.
16. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Wever, M., Richards, S., Dhein, J., Trauth, B. C., Ponstingl, H., and Krammer, P. H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem., 267: 10709–10715, 1992.
17. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169–1178, 1994.
18. Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K. M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301–305, 1989.
19. Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., and Krammer, P. H. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol., 149: 3166–3173, 1992.
20. Leithäuser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Brüderlein, S., Henne, C., Schmidt, A., Debatin, K. M., Krammer, P. H., and Moller, P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69: 415–429, 1993.
21. Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., and Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest., 94: 954–964,1994.
22. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.), 356: 314–317, 1992.
23. Itoh, N., Tsujimoto, Y., and Nagata, S. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol., 151: 621–627, 1993.
24. Weller, M., Malipiero, U. V., Aguzzi, A., Reed, J. C., and Fontana, A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest., in press, 1995.
25. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., and Mountz, J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (Washington DC), 263: 1759–1762, 1994.
26. Wong, G. H. W., and Goeddel, D. V. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J. Immunol., 152: 1751–1755, 1994.
27. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K., and Yonehara, S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological response. Cancer Res., 54: 1580–1586, 1994.
28. Weller, M., Montpied, P., and Paul, S. M. NMDA receptor-mediated excitoprotection of cultured cerebellar granule neurons fails to alter glutamate-induced expression of c-fos and c-jun mRNAs. Mol. Brain Res., 22: 227–235, 1994.
29. preB and λ5 pre-B cell-specific genes can associate with each other and with μ heavy chain. J. Exp. Med., 772: 969–972, 1990.
30. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 769: 1747–1756, 1989.
31. Richardson, B. C., Lalwani, N. D., Johnson, K. J., and Marks, R. M. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol., 24: 2640–2645, 1994.
32. Itoh, N., and Nagata, S. A novel protein domain required for apoptosis. Mutational analysis of human fas antigen. J. Biol. Chem., 268: 10932–10937, 1993.
33. Tartaglia, L. A., Ayres, T. M., Wong, G. H. W., and Goeddel, D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell, 74: 845–853, 1993.
34. Clement, M. V., and Stamenkovic, I. Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions. J. Exp. Med., 180: 557–567, 1994.
35. Wong, G. H. W., Elwell, J. H., Oberley, L. W., and Goeddel, D. V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell, 58: 923–931, 1989.
36. Hashimoto, S., Ishii, A., and Yonehara, S. The Elb oncogene of adenovirus confers cellular resistance to cytotoxicity of tumor necrosis factor and monoclonal anti-Fas antibody. Int. Immunol., 3: 343–351, 1991.
37. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 724:1–6, 1994.
38. Kitada, S., Takayama, S., DeRiel, K., Tanaka, S., and Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4: 71–79, 1994.
39. Schulze-Osthoff, K., Krammer, P. H., and Drdge, W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J., 13: 4587–4596, 1994.
40. Zuber, P., Accolla, R. S., Carrel, S., Diserens, A. C., and De Tribolet, N. Effects of recombinant human tumor necrosis factor-a on the surface phenotype and the growth of human malignant glioma cell lines. Int. J. Cancer., 42: 780–786, 1988.
41. Takiguchi, M., Ting, J. P. Y., Buessow, S. C., Boyer, C., Gillespie, Y., and Frelinger, J. A. Response of glioma cells to interferon-γ: increase in class II RNA, protein and mixed lymphocyte reaction-stimulating ability. Eur. J. Immunol., 75:809–814,1985.
42. Tada, M., Diserens, A. C., Desbaillets, I., and Tribolet, N. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J. Neurosurg., 80: 1063–1073, 1994.